| pubmed-article:19043564 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:19043564 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:19043564 | lifeskim:mentions | umls-concept:C0855056 | lld:lifeskim |
| pubmed-article:19043564 | lifeskim:mentions | umls-concept:C0039736 | lld:lifeskim |
| pubmed-article:19043564 | lifeskim:mentions | umls-concept:C0076080 | lld:lifeskim |
| pubmed-article:19043564 | lifeskim:mentions | umls-concept:C0282460 | lld:lifeskim |
| pubmed-article:19043564 | lifeskim:mentions | umls-concept:C1519810 | lld:lifeskim |
| pubmed-article:19043564 | pubmed:dateCreated | 2008-12-1 | lld:pubmed |
| pubmed-article:19043564 | pubmed:abstractText | We assessed the efficacy of combined temozolomide and thalidomide in patients with unresectable or metastatic leiomyosarcoma in a phase II single-institution trial. Twenty-four patients were enrolled. Temozolomide (150 mg/m(2)/day for 7 days every other week) was administered with concomitant thalidomide (200 mg/day), and continued until unacceptable toxicity or disease progression. There were no complete responses and two (10%) partial responses. Five patients (24%) had stable disease for at least six months. Fourteen patients (67%) progressed after a median of two-month treatment. The median overall survival (twenty-two assessable patients) was 9.5 months [95% CI 7-28 months]. There were no treatment-related deaths or CTC grade 4 toxicities. Thirteen patients were dose-reduced or discontinued thalidomide due to toxicity. In conclusion, this combination of temozolomide and thalidomide provided disease stabilization in a subset of patients with advanced leiomyosarcoma. We hypothesize that temozolomide is the active agent in this regimen, and should be further studied. | lld:pubmed |
| pubmed-article:19043564 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19043564 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19043564 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19043564 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19043564 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19043564 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19043564 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19043564 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19043564 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19043564 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19043564 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19043564 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19043564 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19043564 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19043564 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19043564 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19043564 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19043564 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19043564 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19043564 | pubmed:language | eng | lld:pubmed |
| pubmed-article:19043564 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19043564 | pubmed:status | PubMed-not-MEDLINE | lld:pubmed |
| pubmed-article:19043564 | pubmed:issn | 1357-714X | lld:pubmed |
| pubmed-article:19043564 | pubmed:author | pubmed-author:TaubRobert... | lld:pubmed |
| pubmed-article:19043564 | pubmed:author | pubmed-author:JinZhezhenZ | lld:pubmed |
| pubmed-article:19043564 | pubmed:author | pubmed-author:KeohanMary... | lld:pubmed |
| pubmed-article:19043564 | pubmed:author | pubmed-author:HesdorfferMar... | lld:pubmed |
| pubmed-article:19043564 | pubmed:author | pubmed-author:BoyarMichelle... | lld:pubmed |
| pubmed-article:19043564 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:19043564 | pubmed:volume | 2008 | lld:pubmed |
| pubmed-article:19043564 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:19043564 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:19043564 | pubmed:pagination | 412503 | lld:pubmed |
| pubmed-article:19043564 | pubmed:year | 2008 | lld:pubmed |
| pubmed-article:19043564 | pubmed:articleTitle | Phase II Study of Temozolomide and Thalidomide in Patients with Unresectable or Metastatic Leiomyosarcoma. | lld:pubmed |
| pubmed-article:19043564 | pubmed:affiliation | Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA. | lld:pubmed |
| pubmed-article:19043564 | pubmed:publicationType | Journal Article | lld:pubmed |
